Kazia Therapeutics is progressing its main cancer drug candidate, paxalisib, into Phase 2 trials for colorectal cancer and planning a new breast cancer study. The company recently raised $40 million to support these developments and maintains a strong financial position with low debt and a high current ratio. Investors await the September 4 earnings report, expecting a loss per share of $0.61 and revenues of $0.49 million, typical for a biotech firm in development. These advancements signal potential future growth as Kazia moves closer to commercializing its treatments.
Shell plc completed a $16.5 billion acquisition of ARC Resources Ltd., boosting its production by 370,000 barrels of oil equivalent per day and targeting 4% annual growth through 2030. The company also agreed to acquire the remaining 67% of Tri Star ...
Teladoc Health's BetterHelp segment saw an 11.6% revenue drop and a near-zero profit margin in Q2 2026, partly due to a shift from cash to insurance payments. The company lowered its full-year 2026 revenue guidance to $2.36-$2.45 billion from $2.48-$...
Zscaler reported strong fiscal Q4 results, surpassing analyst expectations with an EPS of $1.19 and revenue of $898.19 million, a 25% year-over-year growth. The company credits its robust performance to strategic investments in artificial intelligenc...
Ciena reported a strong Q3 2026 with adjusted EPS of $2.11, a 215% increase year-over-year, and revenue up 37% to $1.67 billion, driven by high demand from cloud and AI data centers. The company’s backlog rose to $8.5 billion, signaling strong future...
Hutchison China MediTech Limited (HCM) received a Buy rating upgrade from Daiwa with a new price target of $18.50 following a major licensing deal with GSK. The agreement grants GSK exclusive rights to commercialize HCM's experimental cancer therapy ...
